Search   |   Print Page   |   Contact Us   |   Sign In   |   Join
Community Search
THE PATH FORWARD AFTER COVID-19 FOR LIFE SCIENCE STARTUP COMPANIES
Tell a Friend About This EventTell a Friend
 

In spite of having been designated essential businesses, life sciences enterprises, especially startups and early stage companies, are facing significant challenges. How can life sciences companies plan a coherent path forward through the remainder of COVID19 inspired disruptions and beyond. ENET and MDG-Boston have assembled a panel of industry leaders who will share their thoughts.

7/14/2020
When: July 14, 2020
7:00 PM
Where: Online Webinar
United States

« Go to Upcoming Event List  

THE PATH FORWARD AFTER COVID-19 FOR LIFE SCIENCE STARTUP COMPANIES

ENET and MDG (Medical Development Group) are pleased to present  
a Joint Webinar addressing how COVID-19 impacts the life science startup.   

Register now and join us on July 14!
 
Register Here: https://bit.ly/ENET2921w
(Please note capacity is limited so pre-registration is necessary)

While the trend in Massachusetts indicates that COVID-19 infections are abating, it seems increasingly clear that this pandemic crisis will be with us for a while. The disruption to business as usual is obvious and the existential threat to small businesses is real.
In spite of having been designated essential businesses, life sciences enterprises, especially startups and early stage companies, are facing significant challenges. How can life sciences companies plan a coherent path forward through the remainder of COVID19 inspired disruptions and beyond.
ENET and MDG-Boston have assembled a panel of industry leaders who will share their thoughts.

Agenda: 
7:00 - 7:10 PM - ENET Chairperson's announcements
7:10 - 7:15 PM - MDG President's announcements
7:15 - 7:25 PM - eMinute Pitch  - Up to 2 Startup companies' presentations
7:25 - 8:25 PM - 4 expert speakers on the night's topic
8:25 - 8:45 PM - Audience Q & A with the speakers
(all times are USA Eastern Daylight time)


Panel:
Shikha P. Barman, Ph.D., Chief Executive Officer & Co-Founder, Integral BioSystems, and NanoM Therapeutics
Dr. Barman has over 26 years of experience in the translation of innovative concepts from the laboratory into clinical and commercial drug products. She is a founding member of Integral BioSystems, LLC, a drug delivery company contract research organization (CRO) based in Bedford, MA. At Integral, Dr. Barman has built key expertise, personnel, and equipment to serve the industrial drug development community. Integral BioSystems operates on a business model of fee-for-service and innovation. NanoM Therapeutics was spun-off in 2016, to develop products around Integral's proprietary NanoM technology, a sustained release, biodegradable delivery system. This technology was developed to deliver medications in a sustained manner on the ocular surface; additional applications are being contemplated for urology and wound healing.
Dr. Barman served in leadership roles at multiple start-ups in Massachusetts. At Follica, Inc. a start-up founded by Boston-based Puretech Ventures, she was V.P. Pharmaceutical Development developing an innovative hair-growth product. At Inotek Pharmaceuticals, she was Senior Director of Pharmaceutical Development, leading drug delivery in cardiovascular and ophthalmic indications. She was Head of Vaccine and Transdermal Development at Sontra Medical Corporation. At Zycos, Inc., Dr. Barman was Head of Gene Delivery, targeting PLG microsphere-based DNA-based therapies for the treatment of HPV and cancer. Lastly, at Focal, Inc., she helped develop one of first lines of FDA-approved biodegradable tissue sealants. Barman has over 75 issued US Patents and PCTs, 72 publications and 4 book chapters.
Dr. Barman has a dual degree Ph.D in Polymer Science and in Plastics Engineering from University of Massachusetts at Lowell, a M.S. in Polymers from University of Massachusetts at Lowell, a M.S. in Advanced Physical Chemistry and B.S in Chemistry from Auburn University, AL.

Paul Hartung - VP Corporate Development, Neutron Therapeutics
Paul is an experienced life sciences executive with a proven track record in launching successful startup businesses and leading Fortune 500 organizations. He serves on the Boards of Leuko, an award-winning startup developing a non-invasive white blood cell finger test, SemiNex, a profitable semi-conductor laser company. He also serves as a VP of Corporate Development at Neutron Therapeutics, a developer of neutron beam technology for cancer treatment. Paul mentors startups at MIT Venture Mentoring Service, MassCONNECT, and The Capital Network. Paul founded Sonivance, was President & CEO of Cognoptix, and VP of Operations at Winphoria Networks( acquired by Motorola). He managed manufacturing for Summit Technology, Inc., the developer of LASIK(IPO and acquired by Alcon/Novartis). He has held senior management roles at 3Com, Trumpf, Laser Fare and GE. Paul graduated with honors from MIT with an MS Degree in Mechanical Engineering. He is an active speaker, author and inventor on a number of patents.

Carl's career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market. As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products for both consumer and professional markets - he is an inventor on 6 US patents. He served as a Partner at Integral/Analysis Group, a consulting firm focusing on the management of innovation and growth strategy for clients in healthcare and consumer products. He has been an active private equity investor as a member of Angel Healthcare Investors LLC and is a founder of Mass Medical Angels. He has served on the boards of Quosa [research literature management software], Kasalis [robotics], Combinent [women's health], Infobionic [cardiac monitoring], Annovation [anesthetic agent] and currently sits on the board of Syntimmune [immunotherapy], QPID Health [bioinformatics], LifeImage [diagnostic image sharing], Sebacia [dermatology therapy] and the Sudanese Education Fund [philanthropy]. Carl holds an AB degree from Cornell University and received his PhD in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the MIT Sloan School of Management teaching various courses on the topic of biomedical enterprise.


Josef B. Volman - Co-Chair, Business Law, Burns Levinson
Chris is heading the PDD Healthcare Sector. PDD is a design and innovation consultancy with offices in Boston, London, Shanghai and Hong Kong. Chris has experience across healthcare, defense and aerospace. He has spent a lot of time working with medical technology companies, consultancies, early stage life science companies and academics to understand their approach to innovation. He has supported strategy reviews and road mapping process across a variety of physical and digital systems and reviewed for the NSF. He has experience of regulatory aspects and risk management process including test, evaluation and trials. He has managed many formative and summative usability evaluations on a diverse range of medical devices from consumables through to complex dialysis equipment in the UK, US and China. He formed part of the ventilator challenge - a UK based response to COVID-19. Prior to joining PDD, Chris worked on the CHI+MED project at the UCL Interaction Centre (UCLIC), publishing commentaries around need to innovate flexibly and efficiently e.g. Can Standards and Regulations Keep Up With Health Technology? He has guest lectured for the UCL Patient Safety and Clinical Risk Module, as well as a series of short courses relating to the design of healthcare apps.


Moderator:
Roger Frechette, Ph.D., Founder and Principal, NEPAssociates
My daily purpose is to exercise an innate drive to transform ideas and projects into life-changing commercial assets. In the life science business, this is the long game, requiring boundless energy and creativity, coupled with knowledge, experience, and patience.
In my consulting work, I leverage an extensive global network and insights derived from >20 years of experience in business development, calibrated with an extensive science background. My career has encompassed success as a business executive, project/alliance manager and entrepreneur, and also as a scientist, including leadership of discovery/preclinical development teams resulting in a new drug candidate - Paratek Pharmaceuticals NDA's for NUZYRA and SEYSARA NDA's were approved in 2018.

Co-Organizer:
Peter N. Madras, M.D., Lecturer, Institute for Medical Eng and Science, MIT, Former President, Medical Development Group of Boston (MDG Boston)
Dr. Madras, a graduate of McGill Medical School, is a retired transplant and vascular surgeon and Associate Prof. at Harvard Medical School, a founder of two companies and board member of number of start-ups. He is currently lecturer in the Institute for Medical Engineering and Science at MIT and President of the Medical Development Group (MDG Boston). During his practice, Dr. Madras was member and Chairman of the Massachusetts Board of Registration in Medicine. He served for ten years as Medical Director for Grace Biomedical in the development of a liver support system and an artificial pancreas. He has authored 80 papers and holds 3 patents. Prior to his surgical career, Peter was Director of the Medical Group at Avco Everett Research laboratory, which brought to market the first mechanical cardiac assist device, the intra-aortic balloon.  This group was spun off to form five different medical companies, the largest of which is Abiomed.

more News Items
There are currently no news items posted.
more MDG Calendar

8/12/2020
MDG Boston Sponsors Open House

MDG Boston Sponsors

 CONTACT


 Medical Development  Group
 POB 555
 Concord, MA 01742

 

 Email:

 MDGBoston@gmail.com

 NAVIGATION 

 

Home

  

 About Us
 Terms of Use
 Privacy Policy

 

 

  

 

 

 

 



Association Management Software Powered by YourMembership  ::  Legal